Prostate Cancer

News and new technology innovations concerning how imaging technology can help diagnose and treat prostate cancer can be found on this channel.

Dual-labeled PSMA-inhibitors for the diagnosis and therapy of prostate cancer

IMAGE OF THE YEAR: Dual-labeled PSMA-inhibitors for the diagnosis and therapy of prostate cancer. Technology of dual-labeled PSMA-inhibitors for PET/CT imaging and fluorescence-guided intraoperative identification of metastases. This work might help to establish a new treatment regimen for more precise and sensitive pre-, intra- and post-therapeutic detection of prostate cancer.

Credit: Courtesy of A. Baranski, M. Schäfer, U. Bauder-Wüst, M. Roscher, J. Schmidt, E. Stenau, L. Maier-Hein, M. Eder, K. Kopka, German Cancer Research Center, Heidelberg, Germany; T. Simpfendörfer, B. Hadaschik, U. Haberkorn, Heidelberg University Hospital, Heidelberg, Germany; PET-image: Afshar-Oromieh et al., EJNMMI 2013; 40(4); STED-image: J. Matthias, German Cancer Research Center.

This study was supported by the VIP+ fund, Federal Ministry of Education & Research (BMBF), Germany.

Scientific Paper 531: “Preclinical evaluation of dual-labeled PSMA-inhibitors for the diagnosis and therapy of prostate cancer.” A. Baranski, M. Schäfer, U. Bauder-Wüst, M. Roscher, J. Schmidt, E. Stenau, L. Maier-Hein, M. Eder, K. Kopka, German Cancer Research Center (DKFZ), Heidelberg, Germany; T. Simpfendörfer, B.  Hadaschik, U. Haberkorn, University Hospital, Heidelberg, Germany. Presented at SNMMI’s 64th Annual Meeting, June 10-14, 2017, Denver, Colo.

News | Prostate Cancer | June 15, 2017
In the battle against metastatic ...
Targeted MRI Could Pinpoint Aggressive Prostate Cancers Before They Spread

The ZD2-Gd probe, represented by the orange ball and green arrow, binds to the EDB-FN in the prostate cancer cells with high metastatic potential. This results in a strong MRI signal (upper right). Prostate cancer cells with low metastatic potential have no EDB-FN and so there is no MRI signal (lower right). Credit: Han, et al., Bioconjug Chem-Apr-2017

News | Prostate Cancer | May 24, 2017
May 24, 2017 — A research team funded by the National Institute of Biomedical Imaging and Bioengineering (NIBIB) has...
FALCON Trial of Fluciclovine PET/CT Imaging Stops Recruitment after Successful Interim Analysis
News | Radiopharmaceuticals and Tracers | May 15, 2017
May 15, 2017 — Blue Earth Diagnostics announced that the Trial Steering Committee recommended further recruitment be...
News | Prostate Cancer | April 24, 2017
April 24, 2017 — Cancer Targeted Technology recently announced it is focusing on small molecules that target pivotal...
MRI

Multiparametric MRI (MpMRI) has proved helpful in enhancing biopsy sampling for prostate cancer when combined with ultrasound. 

Feature | Prostate Cancer | April 10, 2017 | By Jeff Zagoudis
While prostate cancer is one of the most common cancers among American men — the third leading cause of cancer deaths...
News | Prostate Cancer | April 04, 2017
April 4, 2017 — Profound Medical Corp. announced that the first TULSA-PRO patient paid procedure has been successfully...
Analogic, bkFusion, bk3000, MRI-ultrasound fusion, prostate biopsy, EAU 2017
News | Biopsy Systems | March 30, 2017
March 30, 2017 — Analogic Corp. announced that it will introduce its bkFusion solution for improving biopsy targeting...
high-intensity focused ultrasound, HIFU, prostate tissue ablation, after radiotherapy, EDAP TMS SA, Ablatherm, British Journal of Urology International study
News | Focused Ultrasound Therapy | March 29, 2017
March 29, 2017 — EDAP TMS SA announced the publication of a peer-reviewed article that analyzed Ablatherm Robotic...
VERT, virtual environment radiotherapy, radiation therapy, patient anxiety, Thomas Jefferson University study
News | Radiation Therapy | March 27, 2017
March 27, 2017 — Radiation therapists and physicians know that education can reduce anxiety before radiation treatment...
Karmanos Cancer Institute, UroNav Fusion Biopsy System, prostate cancer
News | Biopsy Systems | March 23, 2017
March 23, 2017 — Urology specialists at the Barbara Ann Karmanos Cancer Institute (Detroit) have begun using the UroNav...
News | Prostate Cancer | March 22, 2017
March 22, 2017 — Profound Medical Corp. announced that it has successfully completed the first sale of a TULSA-PRO...
Exact Imaging, Health Canada approval, ExactVu micro-ultrasound system, prostate biopsies, Sunnybrook Health Sciences Centre, Gregory Czarnota
News | Biopsy Systems | March 16, 2017
March 16, 2017 — Exact Imaging has received Health Canada approval and the corresponding medical device license (#98667...
PET/CT, recurrent prostate cancer, fluciclovine F-18, Emory University

CTVPOST (red) = CTVPRE (yellow) union CTVPET (pink). Also shown (upper right corner) are the PRE (square) vs POST (triangle) dose volume histograms for PTV1, PTV2, rectum, bladder, and penile bulb, showing minimal impact on target coverage or organs at risk dose with the modified targets. Image courtesy of Ashesh B. Jani, M.D., and David Schuster, M.D., Emory University.

News | Radiopharmaceuticals and Tracers | March 16, 2017
March 16, 2017 — The featured clinical investigation article of the March 2017 issue of the ...
Michigan Medicine, Prostate Cancer Risk Clinic, first in the U.S.
News | Prostate Cancer | March 09, 2017
March 9, 2017 — Michigan Medicine and the University of Michigan have launched the nation’s first prostate cancer risk...
prostate cancer, radiation therapy, high-dose-rate brachytherapy, HDR, Red Journal study

This is a single-fraction high-dose-rate prostate implant imaging and dosimetry. Image courtesy of Daniel Krauss/American Society for Radiation Oncology (ASTRO)

News | Brachytherapy Systems | March 06, 2017
March 6, 2017 — Results from a new prospective clinical trial indicate high-dose-rate (HDR)...
Accuray, CyberKnife system, SBRT, long-term disease control, prostate cancer, ASCO GU study
News | Radiation Therapy | February 17, 2017
February 17, 2017 — Accuray Inc. recently announced data from a prospective, Phase II, 17-center study which showed...
ayDCE software, mpMRI, multiparametric magnetic resonance imaging, prostate MRI, RSNA 2017, AHRA, SIIM
Technology | Magnetic Resonance Imaging (MRI) | February 13, 2017
February 13, 2017 —  aycan recently introduced ayDCE software powered by aycan workstation. The new software helps...
Blue Earth Diagnostics, Axumin, fluciclovine F-18, recurrent prostate cancer, Simens PETNET Solutions, increased patient access
News | Radiopharmaceuticals and Tracers | February 07, 2017
February 7, 2017 — Blue Earth Diagnostics and Siemens’ PETNET Solutions announced that an increasing number of...
recurrent prostate cancer, hormone therapy, radiation therapy, Cedars-Sinai study, New England Journal of Medicine
News | Prostate Cancer | February 03, 2017
February 3, 2017 — Adding hormonal therapy to radiation treatment can significantly improve the average long-term...
PET/CT, primary and metastatic prostate cancer, Journal of Nuclear Medicine study, JNM

Ga-68-BBN PET/CT of a 64-year-old man newly diagnosed with prostate cancer by biopsy. Multiple bone metastasis lesions (arrows) were detected. Image courtesy of Jingjing Zhang, Peking Union Medical College, Beijing, China.

News | Prostate Cancer | February 02, 2017
February 2, 2017 — In the featured article from the February 2017 issue of the Journal of Nuclear Medicine, researchers...